Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pavinetant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 known ✓ | P29371 | 20/20 | 1.00 |
| ▸ | TACR2 | P21452 | 6/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | TACR1 | P25103 | 1/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pavinetant SCHEMBL3587478 | 1.00 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Pavinetant SCHEMBL17132260 | 1.00 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3590211 | 0.88 | TACR3 (0.79) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4665567 | 0.88 | TACR3 (0.79) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18407125 | 0.87 | TACR3 (0.80) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4472992 | 0.85 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1582141 | 0.85 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4472989 | 0.85 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1580864 | 0.85 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12049917 | 0.85 | TACR3 (0.78) | TACR3TACR2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704271-B1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250270330-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | KALLYOPE, INC. | 2025-08-28 | — | — | US | claimed |
| US-20250262206-A1 | USE OF TACHYKININ RECEPTOR 3 INHIBITÓR | WUHAN UNIVERSITY (CN) | 2025-08-21 | — | — | US | claimed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | claimed |
| EP-4514351-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | Kallyope, Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| US-20250057830-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2025-02-20 | — | — | US | claimed |
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | claimed |
| US-12083109-B2 | Neurokinin antagonists and uses thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-09-10 | — | — | US | claimed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | claimed |
| CN-118206634-A | Ligand-regulated protein-protein interaction system | 圣安娜儿童癌症研究中心 | 2024-06-18 | — | — | CN | claimed |
| US-20230338355-A1 | NK ANTAGONISTS FOR CONTRACEPTION | ACER THERAPEUTICS INC. | 2023-10-26 | — | — | US | claimed |
| US-20230277518-A1 | NK RECEPTOR ANTAGONISTS FOR CANCER PATIENTS | ACER THERAPEUTICS INC. | 2023-09-07 | — | — | US | claimed |
| WO-2023147134-A2 | METHODS FOR TREATING PATIENTS HAVING LOW ESTROGEN WITH NK3 ANTAGONISTS | ACER THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| WO-2023147135-A1 | NK RECEPTOR ANTAGONISTS FOR TREATMENT OF PROSTATE CANCER | ACER THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| EP-3041509-B1 | NKR3 ANTAGONISTS FOR TREATING OR PREVENTING HOT FLUSHES | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2023-07-12 | — | — | EP | claimed |
| US-20230128029-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-04-27 | — | — | US | claimed |
| US-11458129-B2 | Neurokinin antagonists and uses thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-04 | — | — | US | claimed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | claimed |
| WO-2022026901-A2 | NK ANTAGONISTS FOR CONTRACEPTION | ACER THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026900-A2 | NK RECEPTOR ANTAGONISTS FOR CANCER PATIENTS | ACER THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR3 487/4885TACR2 179/4885CYP1A2 1621/4885 |
| US-20230277518-A1 | NK RECEPTOR ANTAGONISTS FOR CANCER PATIENTS | BDKRB2, KLKB1, BDKRB1 | TACR3 25/4885TACR2 5/4885CYP1A2 2972/4885 |
| US-20230128029-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CRH, NTSR2, TACR2 | TACR3 65/4885TACR2 3/4885CYP1A2 4332/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | TACR3 487/4885TACR2 179/4885CYP1A2 1621/4885 |
| US-20250057830-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CRH, NTSR2, TACR2 | TACR3 65/4885TACR2 3/4885CYP1A2 4332/4885 |
| US-11458129-B2 | Neurokinin antagonists and uses thereof | CRH, NTSR2, TACR2 | TACR3 65/4885TACR2 3/4885CYP1A2 4332/4885 |
| US-20250262206-A1 | USE OF TACHYKININ RECEPTOR 3 INHIBITÓR | TAC3, TACR1, TACR2 | TACR3 4/4885TACR2 3/4885CYP1A2 2766/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR3 487/4885TACR2 179/4885CYP1A2 1621/4885 |
| US-12083109-B2 | Neurokinin antagonists and uses thereof | CRH, NTSR2, TACR2 | TACR3 65/4885TACR2 3/4885CYP1A2 4332/4885 |
| US-20230338355-A1 | NK ANTAGONISTS FOR CONTRACEPTION | KLKB1, KLK3, SHBG | TACR3 42/4885TACR2 5/4885CYP1A2 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.